. That study concluded (at a 95% confidence interval) that an average rabbit pyrogen test laboratory would attain a 50% pass/fail rate with E. coli O55:B5 endotoxin concentrations above 98 pg/ml (or ca. 1.0 ng/kg when the endotoxin is administered at 10 ml/kg per the USP pyrogen test). Therefore, the HIMA task force recommended that 0.1 ng/ml of E. coli 055:B5 endotoxin be the pass/fail limit against which LAL pyrogen test results of medical devices be compared.
This study was carried out to develop conversion factors to relate the potency of three control standard endotoxins (CSEs) to that of the current National Reference Standard Endotoxin (RSE) Escherichia coli 0113:H10:KO, which is identified by the U.S. Pharmacopoeia (USP) as lot F and by the U.S. Food and Drug Administration (FDA) as lot EC-5. The study was sponsored by the Health Industry Manufacturers Association (HIMA) and was encouraged by the FDA's Office of Medical Devices (OMD) as an effort to relate the potency of their joint CSE, Difco Laboratories' (Detroit, Mich.) E. coli 055:B5, to that of the RSE in endotoxin units (EU). The selection of E. coli 055:B5 as the official CSE of the OMD was the result of a previous HIMA collaborative study (1) 
MATERIALS AND METHODS
The following reagents were used for the protocol study: All glassware used in the study was depyrogenated for a minimum of 3 h at a minimum of 180°C or for 1 h at 250°C.
All testing at each laboratory was performed by a single technician on each of 2 days. On each day the technician evaluated the four endotoxins by using two LAL gel clot systems (Pyrogent and Pyrotell). Four replicate assays were performed each day for each endotoxin-lysate combination. Each replicate consisted of a set of twofold serial dilutions of the endotoxin ranging from 400 to 1.5 pg/ml or, in the case of EC-5, from 4 to 0.015 EU/ml accompanied in each case by a negative control. The endpoint assay value for each replicate set was the lowest endotoxin concentration at which the lysate formed a solid gel clot. The log 10 of each endpoint assay value was determined, and the values for each quadruplicate series were averaged to calculate the geometric mean endpoint for each endotoxin. The geometric mean endpoint was expressed in EU per milliliter for EC-5 and in picograms per milliliter for the other three endotoxins (9) .
For purposes of statistical evaluation, the difference on a logarithmic scale between the mean for each control standard endotoxin and the mean for EC-5 was computed for each laboratory-date-lysate combination. For each control standard endotoxin, the mean difference was then computed Tables 1 and 2 .
The variance component analysis used the difference on the logarithmic scale as the dependent variable and included an effect for laboratory (5) . Day-to-day differences within a laboratory constituted the error term in the model. The 95% confidence intervals were computed with the appropriately weighted sum of the two variance components described above.
RESULTS AND DISCUSSION
Results for the phase I study are shown in Table 1 , and results for the phase II study are shown in Table 2 . The geometric mean potencies expressed in EU per nanogram for each of the three control standard endotoxins are remarkably similar for both data sets. In each case, the endotoxin geometric mean potencies produced during the phase 1I study fall within the 95% confidence intervals established by the phase I study.
In general, the intervals for both studies approach those of the twofold dilution limits considered to be statistically acceptable for the gel clot endpoint LAL assay. E. coli 055:B5 and the Novo Pyrexal endotoxin produced relative geometric mean potencies that were insignificantly different as measured by the two lysate test systems. However, the WHO endotoxin produced consistently higher relative potency with Pyrogent than with Pyrotell, reinforcing the requirement of the FDA guidelines and the USP Bacterial Endotoxins Test (9) that the CSE must be recalibrated to the RSE whenever the LAL used is changed. The WHO endotoxin was the weakest of the three control standard endotoxins, and in the Pyrotell lysate test system, it failed to meet the USP Bacterial Endotoxin Test requirement that a CSE possess a potency of not less than 2.0 EU/ng. Finally, it can be established that the Difco E. coli endotoxin lot 504089 used for the original HIMA rabbit pyrogen test collaborative study to set the endotoxin test limits used today by OMD to evaluate pyrogen test results of medical devices contains approximately 4.5 EU/ng when compared with the RSE with Pyrogent and Pyrotell lysates. Thus, the pass/fail endotoxin dose limit (on an activity basis) for medical devices of 0.1 ng/ml (or 1.0 ng/kg when injected into rabbits at 10 ml/kg) is approximately the same as the 5.0-EU/kg endotoxin dose limit established for drugs and
